Pemetrexed Injection

Description :

Pemetrexed Injection 500 mg is taken into use curing malignant pleural mesothelioma in people, whose illness is unresectable; like a single agent for the primary treatment of nearby progressive or metastatic non-small cell lung cancer following prior chemotherapy; in grouping with cisplatin for curing of locally progressive or metastatic non-squamous non-small cell lung cancer; to maintain treatment of people with nearby progressive or metastatic non-squamous non-small cell lung cancer whose illness has not developed following 4 cycles of platinum built first-line chemotherapy.

Additional Information :

• IV Suggested dose is 500 mg/m 2 infused for approximately10 min on day 1 of every 21-day cycle.
  

Side Effects :

• Cardiovascular: Supraventricular arrhythmia (less than 1%).
• CNS: Sensory neuropathy (9%); fatigue (34%); motor neuropathy (1% to 5%).
• Dermatologic: Pruritus (7%); rash/desquamation (14%); erythema multiforme (1% to 5%), alopecia (6%).
• EENT: Increased lacrimation, ocular surface illness comprising conjunctivitis (1% to 5%).
• GI: Anorexia (22%); vomiting (16%); nausea (31%); diarrhea (13%); stomatitis/pharyngitis (15%); mucositis/stomatitis (7%); abdominal pain (1% to 5%); constipation (6%); colitis.
• Genitourinary: Creatinine increased, CrCl decreased, glomerular filtration rate reduced (1% to 5%); renal failure (less than 1%).
• Hematologic-Lymphatic: Leukopenia (12%); neutropenia (11%); anemia, thrombocytopenia (8%); febrile neutropenia (1% to 5%).
• Hepatic: Improved ALT (10%); enlarged AST (8%).
• Hypersensitivity: Allergic reactions/hypersensitivity (1% to 5%).
• Respiratory: Interstitial pneumonitis.
• Miscellaneous: Infection (5%); fever (8%); radiation recall, edema (1% to 5%).